Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-089 in Healthy Volunteers
NCT03103438Phase 1Completed
- Sponsor
- BIOCAD
- Start
- Nov 2016
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of levilimab in rheumatoid arthritis (RA) (7 cohorts), sponsored by BIOCAD. Primary endpoint: Area Under the Plasma Concentration of BCD-089-time Curve From Zero (0) Hours to 1680 Hours After the Single Subcutaneous Injection of BCD-089. Started Nov 2016; status: completed.
02
Drugs
levilimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03103438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03103438.